Literature DB >> 12433768

Prevalence of left ventricular systolic dysfunction and heart failure in high risk patients: community based epidemiological study.

R C Davis1, F D R Hobbs, J E Kenkre, A K Roalfe, R Hare, R J Lancashire, M K Davies.   

Abstract

OBJECTIVES: To determine the prevalence of left ventricular systolic dysfunction, and of heart failure due to different causes, in patients with risk factors for these conditions.
DESIGN: Epidemiological study, including detailed clinical assessment, electrocardiography, and echocardiography.
SETTING: 16 English general practices, representative for socioeconomic status and practice type. PARTICIPANTS: 1062 patients (66% response rate) with previous myocardial infarction, angina, hypertension, or diabetes. MAIN OUTCOME MEASURES: Prevalence of systolic dysfunction, both with and without symptoms, and of heart failure, in groups of patients with each of the risk factors.
RESULTS: Definite systolic dysfunction (ejection fraction <40%) was found in 54/244 (22.1%, 95% confidence interval 17.1% to 27.9%) patients with previous myocardial infarction, 26/321 (8.1%, 5.4% to 11.6%) with angina, 7/388 (1.8%, 0.7% to 3.7%) with hypertension, and 12/208 (5.8%, 3.0% to 9.9%) with diabetes. In each group, approximately half of these patients had symptoms of dyspnoea, and therefore had heart failure. Overall rates of heart failure, defined as symptoms of dyspnoea plus objective evidence of cardiac dysfunction (systolic dysfunction, atrial fibrillation, or clinically significant valve disease) were 16.0% (11.6% to 21.2%) in patients with previous myocardial infarction, 8.4% (5.6% to 12.0%) in those with angina, 2.8% (1.4% to 5.0%) in those with hypertension, and 7.7% (4.5% to 12.2%) in those with diabetes.
CONCLUSION: Many people with ischaemic heart disease or diabetes have systolic dysfunction or heart failure. The data support the need for trials of targeted echocardiographic screening, in view of the major benefits of modern treatment. In contrast, patients with uncomplicated hypertension have similar rates to the general population.

Entities:  

Mesh:

Year:  2002        PMID: 12433768      PMCID: PMC133457          DOI: 10.1136/bmj.325.7373.1156

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  20 in total

1.  European survey of primary care physician perceptions on heart failure diagnosis and management (Euro-HF).

Authors:  F D Hobbs; M I Jones; T F Allan; S Wilson; R Tobias
Journal:  Eur Heart J       Date:  2000-11       Impact factor: 29.983

2.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

Authors:  Salim Yusuf; Bertram Pitt; Clarence E Davis; William B Hood; Jay N Cohn
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

3.  The natural history of congestive heart failure: the Framingham study.

Authors:  P A McKee; W P Castelli; P M McNamara; W B Kannel
Journal:  N Engl J Med       Date:  1971-12-23       Impact factor: 91.245

4.  Epidemiologic aspects of heart failure.

Authors:  G C Sutton
Journal:  Am Heart J       Date:  1990-12       Impact factor: 4.749

5.  Randomised controlled trial of specialist nurse intervention in heart failure.

Authors:  L Blue; E Lang; J J McMurray; A P Davie; T A McDonagh; D R Murdoch; M C Petrie; E Connolly; J Norrie; C E Round; I Ford; C E Morrison
Journal:  BMJ       Date:  2001-09-29

6.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

7.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

Authors:  M A Pfeffer; E Braunwald; L A Moyé; L Basta; E J Brown; T E Cuddy; B R Davis; E M Geltman; S Goldman; G C Flaker
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

8.  Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

Authors: 
Journal:  N Engl J Med       Date:  1987-06-04       Impact factor: 91.245

9.  Evidence of inadequate investigation and treatment of patients with heart failure.

Authors:  K W Clarke; D Gray; J R Hampton
Journal:  Br Heart J       Date:  1994-06

10.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.

Authors:  S Yusuf; B Pitt; C E Davis; W B Hood; J N Cohn
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

View more
  9 in total

1.  Prevalence of conduction abnormalities in a systolic heart failure population by race, ethnicity, and gender.

Authors:  Kathy Hebert; Henry C Quevedo; Leonardo Tamariz; Andre Dias; Dylan L Steen; Rosario A Colombo; Emiliana Franco; Sholom Neistein; Lee M Arcement
Journal:  Ann Noninvasive Electrocardiol       Date:  2012-04       Impact factor: 1.468

2.  Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial.

Authors:  David A Fitzmaurice; F D Richard Hobbs; Sue Jowett; Jonathon Mant; Ellen T Murray; Roger Holder; J P Raftery; S Bryan; Michael Davies; Gregory Y H Lip; T F Allan
Journal:  BMJ       Date:  2007-08-02

3.  Long-term association between self-reported signs and symptoms and heart failure hospitalizations: the Atherosclerosis Risk In Communities (ARIC) Study.

Authors:  Christy L Avery; Katherine T Mills; Lloyd E Chambless; Patricia P Chang; Aaron R Folsom; Thomas H Mosley; Hanyu Ni; Wayne D Rosamond; Lynne Wagenknecht; Joy Wood; Gerardo Heiss
Journal:  Eur J Heart Fail       Date:  2010-01-22       Impact factor: 15.534

4.  Relationship between recommended chronic heart failure treatments and mortality over 8 years in real-world conditions: a pharmacoepidemiological study.

Authors:  Patrick Maison; Gaelle Desamericq; François Hemery; Nicole Elie; Aldo Del'volgo; Jean Luc Dubois-Randé; Luc Hittinger; Isabelle Macquin-Mavier
Journal:  Eur J Clin Pharmacol       Date:  2012-09-21       Impact factor: 2.953

5.  Utilisation of medications recommended for chronic heart failure and the relationship with annual hospitalisation duration in patients over 75 years of age. A pharmacoepidemiological study.

Authors:  Patrick Maison; Patrick Cunin; François Hemery; Florence Fric; Nicole Elie; Aldo Del'volgo; Jean Luc Dubois-Randé; Luc Hittinger; Isabelle Macquin-Mavier
Journal:  Eur J Clin Pharmacol       Date:  2005-06-07       Impact factor: 2.953

Review 6.  Telemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and meta-analysis.

Authors:  Robyn A Clark; Sally C Inglis; Finlay A McAlister; John G F Cleland; Simon Stewart
Journal:  BMJ       Date:  2007-04-10

7.  High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes.

Authors:  L J M Boonman-de Winter; F H Rutten; M J M Cramer; M J Landman; A H Liem; G E H M Rutten; A W Hoes
Journal:  Diabetologia       Date:  2012-05-18       Impact factor: 10.122

8.  Historical trends in survival of hospitalized heart failure patients: 2000 versus 1995.

Authors:  Eyal Shahar; Seungmin Lee
Journal:  BMC Cardiovasc Disord       Date:  2007-01-16       Impact factor: 2.298

9.  A randomised controlled trial and cost effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in the over 65s: (SAFE) [ISRCTN19633732].

Authors:  Dawn Swancutt; Richard Hobbs; David Fitzmaurice; Jonathan Mant; Ellen Murray; Sue Jowett; James Raftery; Stirling Bryan; Michael Davies; Gregory Lip
Journal:  BMC Cardiovasc Disord       Date:  2004-07-29       Impact factor: 2.298

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.